The environmental and metabolic pressures in the tumor microenvironment (TME) play a
key role in molding tumor development by impacting the stromal and immune cell fractions …

Hepatocellular carcinoma (HCC) is the most common form of primary adult liver cancer. After
nearly a decade with sorafenib as the only approved treatment, multiple new agents have …

Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an
increasing mortality rate. Aberrant expression of fibroblast growth factor 19–fibroblast growth …

Resistance becomes major clinical issue in cancer treatment, which strongly limits patients
to benefit from oncotherapy. Growing evidences have been indicative of the critical role of …

Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment
approach for selected patients with urothelial cancer (UC). These agents are changing the …

Fibroblast growth factor (FGF) receptor 4 (FGFR4) belongs to a family of tyrosine kinase
receptor. FGFR4 is highly activated in certain types of cancer and its activation is closely …

Current research in cancer therapy aims to exploit efficient strategies to have long‐lasting
effects on tumors and to reduce or even revoke the chance of recurrence. Within the tumor …

Cancer stands as a serious malady, posing substantial risks to human well‐being and
survival. This underscores the paramount necessity to explore and investigate novel …

Introduction The fibroblast growth factor receptor (FGFR) pathway is essential in cell
proliferation, differentiation, migration, and survival. Cancers such as intrahepatic …

Simple Summary As the most common primary liver cancer, HCC is a tricky cancer resistant
to systemic therapies. The fibroblast growth factor family and its receptors are gaining more …